Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find ...

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

An international collaboration has published groundbreaking research, shedding light on the most significant increase in complexity in the history of life's evolution on Earth: the origin of the ...

The week marked several FDA approvals for drugs and devices, plus data continues to show tarlatamab’s benefit in small cell lung cancer.

Zai Lab's repotrectinib label expansion accepted in China for treating advanced solid tumors with NTRK gene fusion.

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for ...

Zai Lab has an exclusive license agreement with Turning Point Therapeutics, Inc. (a Bristol Myers Squibb company) to develop and commercialize AUGTYRO in Greater China (mainland China, Hong Kong, ...

China’s National Medical Products Administration (NMPA) has accepted Innocare Pharma Ltd.’s NDA for its second-generation pan-tropomyosin receptor kinase inhibitor, zurletrectinib (ICP-723), for ...

The firm submitted data from a registrational study showing the drug's activity in adult and adolescent patients with NTRK fusion-positive solid tumors.

Background: Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 3%–5% of non-small cell lung cancer (NSCLC), and the echinoderm microtubule-associated protein-like 4 gene (EML4) ...